These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 38895628)
1. Concomitant use of renin-angiotensin system inhibitors augments the efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Yu J; Meng F; Sui W; Yu J; Shen J Front Pharmacol; 2024; 15():1378577. PubMed ID: 38895628 [TBL] [Abstract][Full Text] [Related]
2. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y Front Immunol; 2023; 14():1155104. PubMed ID: 37153578 [TBL] [Abstract][Full Text] [Related]
3. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis. Liu C; Guo H; Mao H; Tong J; Yang M; Yan X Front Oncol; 2022; 12():753234. PubMed ID: 35280736 [TBL] [Abstract][Full Text] [Related]
4. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X Front Oncol; 2022; 12():976224. PubMed ID: 36185176 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Huang T; Chen X; Zhang H; Liang Y; Li L; Wei H; Sun W; Wang Y Front Oncol; 2021; 11():706652. PubMed ID: 34395281 [TBL] [Abstract][Full Text] [Related]
6. Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis. Zou D; Song A; Yong W Front Oncol; 2023; 13():1176574. PubMed ID: 37621675 [TBL] [Abstract][Full Text] [Related]
7. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J Front Oncol; 2022; 12():962173. PubMed ID: 36059629 [TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y Front Immunol; 2023; 14():1173952. PubMed ID: 37313406 [TBL] [Abstract][Full Text] [Related]
9. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y Front Oncol; 2022; 12():968517. PubMed ID: 36439448 [TBL] [Abstract][Full Text] [Related]
10. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X Front Oncol; 2022; 12():978069. PubMed ID: 36330494 [TBL] [Abstract][Full Text] [Related]
11. Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review. Li H; Zhang L; Yang F; Zhao R; Li X; Li H Front Immunol; 2023; 14():1218386. PubMed ID: 37841249 [TBL] [Abstract][Full Text] [Related]
12. Clinical evidence for the prognostic impact of metformin in cancer patients treated with immune checkpoint inhibitors. Shen J; Ye X; Hou H; Wang Y Int Immunopharmacol; 2024 Jun; 134():112243. PubMed ID: 38735258 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ling T; Zhang L; Peng R; Yue C; Huang L Front Immunol; 2022; 13():1014063. PubMed ID: 36466905 [TBL] [Abstract][Full Text] [Related]
14. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients. Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H Front Oncol; 2021; 11():627016. PubMed ID: 34513654 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Qian X; Chen H; Tao Y Front Immunol; 2023; 14():1146898. PubMed ID: 37063822 [TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen X; Meng F; Jiang R Front Oncol; 2021; 11():746976. PubMed ID: 34900692 [TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Crespin A; Le Bescop C; de Gunzburg J; Vitry F; Zalcman G; Cervesi J; Bandinelli PA Front Oncol; 2023; 13():1075593. PubMed ID: 36937417 [TBL] [Abstract][Full Text] [Related]
18. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis. Ke L; Li S; Cui H BMC Cancer; 2022 Nov; 22(1):1185. PubMed ID: 36397030 [TBL] [Abstract][Full Text] [Related]
19. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen H; Han KD; He ZJ; Huang YS Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149 [TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system inhibitors improve the survival of cholangiocarcinoma: a propensity score-matched cohort study. Zhu XX; Li JH; Fang P; Qu XF; Liang LJ; Lai JM; Yin XY BMC Cancer; 2023 Sep; 23(1):826. PubMed ID: 37670280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]